<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662452</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG2222-CL-101</org_study_id>
    <secondary_id>2015-004466-29</secondary_id>
    <nct_id>NCT02662452</nct_id>
  </id_info>
  <brief_title>First-in-Human Single and Multiple Dose of GLPG2222</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, First-in-Human Study of GLPG2222 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this First-in-Human study is to evaluate the safety and tolerability after&#xD;
      single ascending oral doses of GLPG2222 given to healthy subjects, compared to placebo (Part&#xD;
      1). Also, the safety and tolerability of multiple ascending oral doses of GLPG2222 given to&#xD;
      healthy subjects daily for 14 days compared to placebo, will be evaluated (Part 2).&#xD;
&#xD;
      Furthermore, during the course of the study after single and multiple oral dose&#xD;
      administrations, the amount of GLPG2222 present in the blood and urine (pharmacokinetics)&#xD;
      will be characterized.&#xD;
&#xD;
      The potential of cytochrome P450 (CYP)3A4 interaction after repeated dosing with GLPG2222&#xD;
      will be explored as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with adverse events</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with abnormal laboratory parameters</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with abnormal vital signs</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with abnormal electrocardiogram</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with abnormal physical examination</measure>
    <time_frame>Between screening and 7-10 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change versus placebo in number of subjects with abnormal pulmonary function</measure>
    <time_frame>Between screening and 4 days after the last dose (Part 1 only)</time_frame>
    <description>To evaluate the safety and tolerability of GLPG2222 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of abnormal pulmonary function as measured by spirometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of GLPG2222 in plasma</measure>
    <time_frame>Between Day 1 predose and 48 hours after the (last) dose</time_frame>
    <description>To characterize the amount of GLPG2222 in plasma over time - pharmacokinetics (PK) - after a single oral dose and multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of GLPG2222 in urine</measure>
    <time_frame>Between Day 1 predose and 24 hours after the (last) dose</time_frame>
    <description>To characterize the amount of GLPG2222 in urine over time - pharmacokinetics (PK) - after a single oral dose and multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 6-b-hydroxycortisol/cortisol in urine</measure>
    <time_frame>Twelve hours before dosing on Day 1 and Day 14</time_frame>
    <description>To assess the potential of CYP3A4 interaction after repeated oral dosing with GLPG2222 by means of the ratio of 6-b-hydroxycortisol/cortisol in urine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG2222 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG2222 oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG2222 multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG2222 oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 single dose</intervention_name>
    <description>single ascending doses, oral suspension</description>
    <arm_group_label>GLPG2222 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single dose</intervention_name>
    <description>single doses, oral suspension, matching placebo</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG2222 multiple doses</intervention_name>
    <description>multiple ascending doses, daily for 14 days, oral suspension</description>
    <arm_group_label>GLPG2222 multiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo multiple doses</intervention_name>
    <description>multiple doses, daily for 14 days, oral suspension, matching placebo</description>
    <arm_group_label>Placebo multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males between 18-50 years of age&#xD;
&#xD;
          -  Subjects must have a body mass index between 18-30 kg/m²&#xD;
&#xD;
          -  Subjects must be judged to be in good health based upon the results of a medical&#xD;
             history, physical examination, vital signs, 12-lead electrocardiogram and laboratory&#xD;
             profile&#xD;
&#xD;
          -  Subjects must have a screening spirometry with forced expiratory volume in 1 second&#xD;
             ≥80% of predicted values for age, gender and height (Part 1 only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject with a known hypersensitivity to study drug ingredients or a significant&#xD;
             allergic reaction to any drug&#xD;
&#xD;
          -  Concurrent participation or participation within 8 weeks prior to the initial study&#xD;
             drug administration in a drug/device or biologic investigational research study&#xD;
&#xD;
          -  A subject with active drug or alcohol abuse within 2 years prior to the initial study&#xD;
             drug administration&#xD;
&#xD;
          -  Current sexually active (and/or child wish) male; a contraception method must be used&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsteen Donaldson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS LSS Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

